Literature DB >> 31767966

High-risk retinoblastoma based on age at primary enucleation: a study of 616 eyes.

Swathi Kaliki1, Shweta Gupta2, George Ramappa2, Ashik Mohamed3, Dilip K Mishra4.   

Abstract

PURPOSE: To study the high-risk histopathology features of retinoblastoma based on age at primary enucleation.
METHODS: Retrospective study of 616 patients.
RESULTS: The mean age at presentation and primary enucleation for retinoblastoma was 34 months (median, 28 months; range, <1-455 months). Of these cases, 128 (21%) were aged ≤1 year, 149 (24%) were in the age group of 1-2 years, 117 (19%) in 2-3 years, 104 (17%) in 3-4 years, and 118 (19%) were >4 years of age at the time of enucleation. Bilateral retinoblastoma (34%; p < 0.0001) and buphthalmos (20%; p < 0.0001) were more common in children ≤1 year of age. Anterior chamber pseudohypopyon (15%; p < 0.0001) and vitreous seeds (53%; p < 0.0001) were more common in children aged >4 years. Based on 8th edition American Joint Committee on Cancer staging system, pT3 was less common in children ≤1 year of age (13%; p < 0.001). Based on histopathology, 38% patients had high-risk features including 24% children aged ≤1 year, 42% in the age group of 1-2 years, 34% in 2-3 years age group, 45% in 3-4 years age group, and 48% patients were >4 years of age. Post-laminar optic nerve infiltration (6%; p = 0.02) and massive choroidal infiltration (9%; p = 0.04) was least common in children ≤1 year of age. Over a mean follow-up period of 52 months (median, 36 months; range, <1-218 months), systemic metastasis and death occurred in 9% patients despite adjuvant systemic chemotherapy.
CONCLUSION: The predominant high-risk histopathology feature of retinoblastoma varies with age at primary enucleation.

Entities:  

Mesh:

Year:  2019        PMID: 31767966      PMCID: PMC7376026          DOI: 10.1038/s41433-019-0698-2

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  4 in total

1.  The evaluation and current concept of retinoblastoma therapy.

Authors:  A B REESE; R M ELLSWORTH
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1963 Mar-Apr

2.  Proteoglycan composition in the human sclera during growth and aging.

Authors:  J A Rada; V R Achen; S Penugonda; R W Schmidt; B A Mount
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-06       Impact factor: 4.799

3.  High-risk features and tumor differentiation in retinoblastoma: a retrospective histopathologic study.

Authors:  Ralph C Eagle
Journal:  Arch Pathol Lab Med       Date:  2009-08       Impact factor: 5.534

4.  Anterior diffuse retinoblastoma: mutational analysis and immunofluorescence staining.

Authors:  Michelle B Crosby; G Baker Hubbard; Brenda L Gallie; Hans E Grossniklaus
Journal:  Arch Pathol Lab Med       Date:  2009-08       Impact factor: 5.534

  4 in total
  3 in total

1.  High risk histopathological factors in retinoblastoma in upfront enucleated eyes: An experience from a tertiary care centre of Pakistan.

Authors:  Nausheen Yaqoob; Salima Mansoor; Kanwal Aftab; Bushra Kaleem; Ahmer Hamid; Saba Jamal
Journal:  Pak J Med Sci       Date:  2022-01       Impact factor: 1.088

2.  Anatomo-Clinical Aspects of Retinoblastoma: A Series of 144 Cases.

Authors:  Fidélia Nihad Da Silva; Lafia Xavier Kora; Tania Elongo; Asmaa El Kebir; Loubna El Maaloum; Nisrine Bennani-Guebessi; Bouchra Allali; Asmaa El Kettani; Mehdi Karkouri
Journal:  Cureus       Date:  2022-05-27

3.  LncRNA NEAT1 Acts as an miR-148b-3p Sponge to Regulate ROCK1 Inhibition of Retinoblastoma Growth.

Authors:  Hang Lu; Zhenjun Zhang; Yao Lu; Weiwei Xiu; Jinglin Cui
Journal:  Cancer Manag Res       Date:  2021-07-12       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.